Related Experiment Video
Updated: Feb 4, 2026

Ganglioside Extraction, Purification and Profiling
Published on: March 12, 2021
GM3(Neu5Gc) ganglioside: an evolution fixed neoantigen for cancer immunotherapy
Mayrel Labrada1, Denise Dorvignit1, Giselle Hevia1
1Immunobiology Division, Molecular Immunology Institute, Center of Molecular Immunology (CIM), Playa, Havana, Cuba.
Abstract:
Numerous molecules have been considered as targets for cancer immunotherapy because of their levels of expression on tumor cells, their putative importance for tumor biology, and relative immunogenicity. In this review we focus on the ganglioside GM3(Neu5Gc), a glycosphingolipid present on the outer side of the plasma membrane of vertebrate cells. The reasons for selecting GM3(Neu5Gc) as a tumor-specific antigen and its use as a target for cancer immunotherapy are discussed, together with the development of antitumor therapies focused on this target by the Center of Molecular Immunology (CIM, Cuba).
Related Concept Videos
The Evidence for Evolution
Convergent Evolution
Tumor Immunotherapy
Fixing Double-strand Breaks
Eukaryotic Evolution
Contrary to the endosymbiont theory, the eukaryote-first hypothesis proposes that the simpler prokaryotic and...
Synteny and Evolution
Around 80 million years ago, the human and mice lineages diverged from the common ancestor. During the course of evolution, the ancestral...

